Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,725.35
(
0.39%
)
US TECH 100
24,141.60
(
0.53%
)
Dow Jones
47,106.58
(
0.34%
)
Brent Oil
100.30
(
2.03%
)
Bitcoin
74,352.94
(
-0.66%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Regulardoc post# 133794

Saturday, 12/24/2011 4:33:40 PM

Saturday, December 24, 2011 4:33:40 PM

Post# of 257251

Who pays for the costs of clinical trials for the first two compounds?

BAX does. For the first two FoB’s in the collaboration, MNTA pays for pre-IND process development and is reimbursed by BAX via the $91M in technical/development milestones (#msg-70258421, #msg-70234186). After the IND filing for each of the first two compounds, BAX bears all of the development and commercialization costs.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now